Clinical Trial Update: Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating KITE-439 in HLA-A*02:01+ adults with HPV16+ relapsed/refractory cancers was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus-related Cancers
• Or Refractory Cancer

Drugs mentioned

• KITE-439

Snippet

Sponsor: Gilead Sciences | Conditions: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | Phase 1 | Status: TERMINATED | Results posted: 2023-12-26